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BCAT1 controls metabolic reprogramming in
activated human macrophages and is associated
with inﬂammatory diseases
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Branched-chain aminotransferases (BCAT) are enzymes that initiate the catabolism of
branched-chain amino acids (BCAA), such as leucine, thereby providing macromolecule
precursors; however, the function of BCATs in macrophages is unknown. Here we show that
BCAT1 is the predominant BCAT isoform in human primary macrophages. We identify
ERG240 as a leucine analogue that blocks BCAT1 activity. Selective inhibition of BCAT1
activity results in decreased oxygen consumption and glycolysis. This decrease is associated
with reduced IRG1 levels and itaconate synthesis, suggesting involvement of BCAA
catabolism through the IRG1/itaconate axis within the tricarboxylic acid cycle in activated
macrophages. ERG240 suppresses production of IRG1 and itaconate in mice and contributes
to a less proinﬂammatory transcriptome signature. Oral administration of ERG240 reduces
the severity of collagen-induced arthritis in mice and crescentic glomerulonephritis in rats,
in part by decreasing macrophage inﬁltration. These results establish a regulatory role for
BCAT1 in macrophage function with therapeutic implications for inﬂammatory conditions.
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ranched-chain aminotransferase (BCAT) is the enzyme
responsible for the reversible transamination of leucine,
isoleucine and valine, the amino acids collectively known as
branched-chain amino acids (BCAA). Transamination of BCAAs
is the ﬁrst step in their catabolism and results in the formation of
branched-chain a-keto acids, which are decarboxylated to form
derivatives of coenzyme A (CoA)1,2. In the case of leucine,
transamination leads to the formation of a-ketoisocaproate,
which is further metabolized to form the ketone body
acetoacetate, and acetyl-CoA, which is subsequently oxidized in
the tricarboxylic acid (TCA) cycle. This reaction equally results in
the production of glutamate, which is another crucial metabolite
that feeds into the TCA cycle at the level of a-ketoglutarate3.
Hence, BCAT enzymes are multi-level regulators of the TCA
cycle and oxidative phosphorylation, possibly contributing to
metabolic reprogramming in eukaryotic cells.
BCAT exists in two isoforms, mitochondrial BCAT2 and
cytosolic BCAT1. Although Bcat2 is expressed ubiquitously in
most tissues and especially in skeletal muscle, tissues of the
digestive system and the kidney, Bcat1 expression is reported to
be limited to embryonic tissues, adult brain, ovary, placenta and
neurons of the peripheral nervous system4. Despite the large body
of work on BCAA metabolism and, in particular, Bcat1 activity
in glutamate neurotransmitter metabolism in the brain4 and in
tumour growth5, data on the role of BCAT1 and its potential
metabolic effects on macrophages and inﬂammatory disease in
general do not exist.
Macrophages are innate immune cells with a phenotype tightly
linked to their metabolism6–9. They have remarkable plasticity
in function, with both extreme and intermediate activation
phenotypes10,11 under speciﬁc transcriptional control12. Toll-like
receptor agonist lipopolysaccharide (LPS) stimulation results in a
rapid and robust transcriptional response that involves genes that
regulate metabolic reprogramming13. Macrophages activated by
LPS undergo a metabolic shift from oxidative phosphorylation to
glycolysis known as the Warburg effect9,14, with some important
metabolic effectors regulating the balance between the two
metabolic states15. The increased consumption of glucose is
known to be associated with a proinﬂammatory macrophage
phenotype16. Similar metabolic reprogramming has been
detected in mouse dendritic cells, with an early response to LPS
corresponding to an increase in glycolytic rate within minutes
of exposure17. Macrophages activated by LPS also show accumu-
lation of Krebs cycle intermediates, such as succinate, regulating
Hif-1a-mediated IL-1b production14. A comprehensive
integrative analysis of the transcriptome and metabolome in
activated macrophages has established the importance of citrate-
itaconic acid axis through Irg1 (also known as cis-aconitate
decarboxylase, Acod1)18, one of the most signiﬁcantly
up-regulated transcripts in LPS-stimulated macrophages, which
encodes an enzyme that catalyses the aconitate-to-itaconate
reaction18,19. These studies led to the concept of the broken
(or fragmented) Krebs cycle in LPS-activated macrophages
(M(LPS))18,20, in which TCA cycle intermediate metabolites
function as metabolic checkpoints for the activation of LPS
response genes, such as Hif1a, Il1b, Irg1. Furthermore, these data
show that reprogramming macrophage metabolism is not only
needed for energy requirements, but also for the transcriptional
regulation of the innate immune response.
By using high-throughput RNA measurements in human
monocyte-derived macrophages, we show that BCAT1 is the most
abundantly expressed BCAT isoform. Using a novel selective
inhibitor of BCAT1 (ERG240, a leucine analogue), we show that
inhibition of BCAT1 leads to the reduction of oxygen consump-
tion and glycolysis together with a decrease in IRG1 and
itaconate, but not HIF-1a and IL-1b messenger RNA (mRNA)
and protein levels; suggesting induction of BCAT1-mediated
anaplerosis through the leucine–citrate–itaconic acid axis in early
macrophage activation with LPS. To conﬁrm the effect of
ERG240 in vivo, we show that peritoneal macrophages from
mice injected with LPS and ERG240 have reduced levels of
Irg1/itaconate together with a diminished proinﬂammatory
transcriptome when compared with mice injected with LPS
alone. RNAi of BCAT1 in human M (LPS) phenocopies the effect
of pharmacological blockade with reduced BCAT1 protein levels
resulting in reduction of oxygen consumption and glycolysis
together with decreased IRG1 and itaconate levels. We then
investigate the anti-inﬂammatory effects of ERG240 in two
distinct murine models of autoimmune disease (rheumatoid
arthritis and crescentic glomerulonephritis) characterized by
macrophage activity and inﬁltration. We show that ERG240
treatment results in reduced inﬂammation associated with
decreased macrophage inﬁltration in target organs (joints and
kidney) in both models.
Results
BCAT1 regulates metabolic reprogramming in macrophages.
In a previous genome-wide expression quantitative trait loci
analysis using inbred rat models of glomerulonephritis, we
identiﬁed Bcat1 as the hub of a co-expression network in mac-
rophages, suggesting its potential regulatory metabolic role in
inﬂammatory disease21. To gain more insights into the role of
BCAT enzymes in macrophages, we set out to investigate these in
human monocyte-derived macrophages (hMDMs) by subjecting
these cells to RNA-sequencing (Fig. 1a). This showed that mRNA
levels of BCAT1 are markedly increased when compared to
BCAT2, suggesting that the cytoplasmic isoform is the major
source of BCAA catabolism in these cells. To examine the role of
BCAT1 in macrophage metabolism and inﬂammatory diseases,
we identiﬁed a novel BCAT1 inhibitor, ERG240, using molecular
modelling approaches based on the X-ray crystal structures
of BCAT1 (ref. 22). ERG240 is a water-soluble structural analogue
of leucine (Fig. 1b). Its ability to suppress the BCAT1
aminotransferase activity was measured in a continuous
ﬂuorometric assay (ref. 23 and see Supplementary Methods).
We found that ERG240 inhibited recombinant BCAT1 with an
IC50 of 0.1–1 nM, while no inhibition was observed on BCAT2
(Fig. 1c). The effect of BCAT1 inhibition on hMDMs was studied
in control (basal, M(basal)) or LPS-stimulated cells by measuring
mRNA and protein levels of three major TCA-regulated early
macrophage activation markers: HIF-1a, IL-1b (ref. 14) and IRG1
(ACOD1)18. As expected, LPS treatment caused the up-regulation
of HIF-1a, IL-1b and IRG1 at mRNA and protein levels
(Fig. 1d,e). Strikingly, treatment with ERG240 (3 h, 20mM)
resulted in a dramatic reduction in IRG1 mRNA levels but not
HIF1A and IL1B in LPS-stimulated cells (Fig. 1d). These results
were also conﬁrmed at the IRG1 protein levels in LPS and
ERG240-treated cells (Fig. 1e). Consequently, the ERG240-
mediated reduction in IRG1 levels resulted in decreased
itaconate levels measured by GC/MS (Fig. 1f). ERG240 had
comparable inhibitory effect on IRG1 expression in TNF-
stimulated human macrophages (Supplementary Fig. 1A) and
long-term exposure (24 h) to LPS and ERG240 resulted in
reduced IL-1b levels (Supplementary Fig. 1B), suggesting a
temporal effect of ERG240 on IL-1b. Furthermore, short-term
exposure of ERG240 signiﬁcantly reduced TNF and NOS2 but not
IL6 and PTGS2 expression levels in human macrophages
(Supplementary Fig. 1F). ERG240 did not affect cell viability at
3 and 8 h LPS stimulation in neither control nor LPS-treated
human macrophages (Supplementary Fig. 1E). Importantly, the
effect of BCAT1 inhibition on IRG1 expression and itaconate
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Figure 1 | BCAT1 expression and inhibition in human macrophages. (a) RNA-sequencing in human monocyte-derived macrophages (hMDMs) shows
mRNA copies of BCAT enzymes in normalized counts. n¼ 14 healthy donor hMDMs were used for RNA-seq. (b) Chemical structure of ERG240 and
leucine. (c) Enzymatic activity of recombinant human BCAT1 and BCAT2 in presence of ERG240. (d) Relative expression of IRG1, HIF1A and IL1B measured
by qRT-PCR in control, ERG240-treated (20mM, 3 h), LPS treated (100 ngml 1, 3 h), and LPSþ ERG240 treated (LPS, 100 ngml 1; ERG240, 20mM for
3 h) hMDMs. ns, non-signiﬁcant. All expression values are normalized to those obtained for HPRTgene expression. n¼ 3 healthy donor hMDMs were used
in each group. (e) Western blot analysis of IRG1, IL-1b, HIF-1a and beta-actin (ACTB) in control (untreated), ERG240-treated (20mM, 3 h), LPS treated
(100 ngml 1, 3 h) and LPSþ ERG240 treated (LPS, 100 ngml 1; ERG240, 20mM for 3 h) hMDMs. The experiment is representative of three independent
experiments using n¼ 3 healthy donor hMDMs each. (f) GC/MS results showing itaconic acid production in hMDMs in presence or absence of ERG240
(20mM). LPS treatment was for 8 h (100 ngml 1). GC/MS plot for each donor is shown separately where itaconate abundance denotes arbitrary units.
Error bars are s.e.m. Signiﬁcance was tested using two-tailed Student’s t-test or one-way ANOVA. * Po10 3 following two-way ANOVA.
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levels was ascertained in macrophages stimulated with LPS in a
BCAA-deprived media (Supplementary Fig. 1C and D),
conﬁrming the requirement for an enzymatically active BCAT1
for its inhibition of IRG1-mediated itaconate production.
Next, we measured the effect of BCAT1 inhibition on oxygen
consumption and glycolysis in hMDMs. The mitochondrial
respiration and glycolytic metabolism were assessed by measure-
ment of oxygen consumption rate (OCR) and extracellular
acidiﬁcation rates (ECAR), respectively. The bioenergetic proﬁles
were determined by sequential use of oligomycin (mitochondrial
ATP synthase inhibitor), FCCP (protonophore and uncoupler of
ATP synthesis from mitochondrial respiration), and a combina-
tion of rotenone, antimycin A and 2-deoxyglucose (2-DG) that
allows the inhibition of mitochondrial respiration and glycolysis.
LPS treatment alone resulted in increased OCR (basal respiration,
estimated ATP production and maximal respiration) and ECAR
(glycolysis and glycolytic capacity) in hMDMs (Supplementary
Fig. 2). Treatment of LPS-stimulated hMDMs with ERG240
resulted in decreased OCR and ECAR (Fig. 2a,b). This translated
into a signiﬁcantly reduced basal respiration, estimated ATP
production, maximal respiration, glycolysis and glycolytic
capacity (Fig. 2a,b). In keeping with the decreasing effect of
ERG240 on oxygen consumption and glycolysis, siRNA-mediated
inhibition of BCAT1 mRNA levels resulted in a signiﬁcant
decrease in OCR and ECAR levels (Fig. 2c,d). We also measured
citrate by GC/MS in hMDMs as the breakpoint TCA metabolite
in M(LPS)18 and found a relative increase in citrate levels
following LPS stimulation, which was further signiﬁcantly
increased in the presence of ERG240 (Supplementary Fig. 3A),
suggesting that the effect of BCAT1 inhibition on the broken
TCA cycle in human macrophages lies predominantly
downstream citrate at the IRG1 site with a relatively minor
effect through inhibition of BCAA transamination and reduction
in the amount of acetyl-coA entering the cycle (Supplementary
Fig. 3B). To conﬁrm the pharmacological inhibition with
ERG240, we used RNAi on human BCAT1 to measure IRG1
protein levels and itaconate (Fig. 3a). The experiment showed
consistent knock down of BCAT1 associated with reduced IRG1
levels in three independent donors (Fig. 3a). In keeping with the
pharmacological blockade, BCAT1 knockdown resulted in
reduced IRG1 and itaconate levels in hMDMs (Fig. 3b).
ERG240 suppresses in vivo production of IRG1/itaconate.
To conﬁrm the inhibitory effect of ERG240 on IRG1-mediated
itaconate production in M(LPS) in vivo, we injected C57BL/6
mice with either LPS (1.5mg kg 1) or LPS in conjunction with
ERG240 (500mg kg 1), and harvested peritoneal macrophages
24 h later. These results showed a reduction in Irg1 mRNA and
protein levels associated with a signiﬁcant decrease in itaconate
(Fig. 4a–c). Itaconate was equally decreased when ERG240 was
administered 3 h after the ﬁrst LPS injection (Fig. 4c).
To gain more insights into the effect of ERG240 on
macrophage polarization, we performed RNA-sequencing
(RNA-seq) in vehicle, LPS and LPSþ ERG240 treated peritoneal
macrophages at the time of collection (24 h). When the top 100
(97 annotated, 28 up-regulated and 72 down-regulated) differ-
entially expressed transcripts (10 310oFDR o10 73) between
LPS and LPSþ ERG240 treated groups were analysed by STRING
for high conﬁdence protein-protein interactions (interaction
score¼ 0.7), this led to the identiﬁcation of an interferon
(IFN)-inducible GTPase pathway (PFAM protein domains
FDR¼ 6.97 10 6; Fig. 4d). Interestingly, all of the 25 genes
belonging to the IFN-inducible GTPase signature are down-
regulated together with M1-like markers (Nos2, Il6), while M2-
like and extracellular matrix transcripts are up-regulated in the
peritoneal macrophages obtained from ERG240-treated mice
(Fig. 4e-g). Mrc1, Klf4 and Cd36 were previously described as
alternative (M2-like) macrophage activation markers24–26, and
Fragments Per Kilobase of transcript per Million fragments
mapped (FPKM) values for these transcripts show signiﬁcant
up-regulation in ERG240-treated macrophages (Fig. 4g). Iﬁt and
Gbp gene families’ expression values are also illustrated in
Fig. 4g. Furthermore, the extracellular matrix enrichment is
striking (Cellular component GO: extracellular space,
FDR¼ 1.04 10 8) among the 28 most signiﬁcantly up-
regulated genes. FPKM values. FPKM values for Fn1, Mmp9,
Gsn and Spp1 are shown in Fig. 4g. Taken together, these results
show that long-term ERG240 exposure in LPS-injected mice is
associated with a reduced proinﬂammatory and increased anti-
inﬂammatory and repair transcriptome signature in peritoneal
macrophages.
ERG240 reduces the severity of immune-mediated inﬂammation.
First, a dose-escalating toxicity study was performed and indi-
cated that no major adverse effects were associated with the oral
or intraperitoneal administration of ERG240 when the drug was
given at doses up to 2 g kg 1. A subsequent pharmacokinetics
study revealed that ERG240 showed excellent bioavailability with
a relatively short half-life in plasma suggesting either rapid
absorption or clearance of the drug (Tables 1 and 2).
The reduced proinﬂammatory transcriptome signature
following treatment with ERG240 in the peritoneal macrophages
of LPS-injected mice led us hypothesize that BCAT1 blockade
could be beneﬁcial in broader inﬂammatory conditions. To test
the potential anti-inﬂammatory effects of ERG240 in a macro-
phage-dependent model of immune complex-driven tissue
inﬂammation, we assessed the effect of ERG240 administration
in the well-established nephrotoxic nephritis (NTN) model
utilizing the uniquely susceptible Wistar-Kyoto (WKY) rat
strain27,28. The macrophage-dependent kidney inﬂammation
observed in this model resembles the immune complex
mediated glomerular damage in systemic lupus erythematosus
referred as lupus nephritis29. Oral administration of ERG240
during 10 days following NTN induction resulted in signiﬁcantly
reduced glomerular crescent formation, proteinuria, and serum
creatinine (Fig. 5a), demonstrating the ability of ERG240 to
reduce the severity of inﬂammation in a highly reproducible and
severe model of antibody-mediated kidney inﬂammation.
Treatment with ERG240 did not interfere with the deposition
of the nephrotoxic serum to the glomerular basement membrane.
Quantitative immunoﬂuorescence for collagen type I alpha I
(Cola1) in nephritic kidneys (day 28) showed a signiﬁcant
down-regulation in the ERG240-treated animals (Fig. 5b), which
was in accordance with the reduced Sirius red staining and
Col1a1 mRNA levels in the renal cortex (Fig. 5b). These results
showed that treatment with ERG240 resulted in reduced
interstitial ﬁbrosis in the NTN model of crescentic
glomerulonephritis.
In addition to NTN, macrophages play a central role in the
pathogenesis of rheumatoid arthritis (RA) where they inﬁltrate
synovial membranes30,31, contributing to chronic inﬂammation.
Bone erosion in RA has also been linked to monocytes/
macrophages since these cells are known to differentiate into
osteoclasts in the presence of M-CSF and RANKL32. Hence, the
effect of Bcat1 inhibition on collagen-induced arthritis (CIA)
in mice was examined prophylactically, by administering
720mg kg 1 ERG240 at the time of the booster injection
21 days after the initial immunization, and therapeutically,
by administering 1000mg kg 1 ERG240 after arthritis was
established. The results show that oral administration of
ERG240 alleviates the severity of CIA (Fig. 5c). Analysis of the
sera obtained before immunization and at the end of the
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Figure 2 | BCAT1 inhibition reduces oxygen consumption and glycolysis in human macrophages. (a) Real-time extracellular OCR measurements in
hMDMs (left panel) that were previously treated with either LPS (100ngml 1) or LPSþ ERG240 (20mM) for 3 h. OCR values were recorded following
sequential treatments with glucose (5mM), oligomycin A (0.5mM), carbonyl cyanide 4-(triﬂuoromethoxy) phenyl- hydrazine (FCCP, 1 mM) and a
combination of 2-deoxy-D-glucose (2-DG, 50mM), antimycin A (1 mM) and rotenone (1mM). Basal respiration, estimated ATP production, and maximal
respiration are shown in the right panel. n¼ 3 healthy donor hMDMs were used in 12 technical replicates. The results are representative of three
independent experiments. (b) Real-time ECAR (left panel), glycolysis and glycolytic capacity (right panel). n¼ 3 healthy donor hMDMs were used in
12 technical replicates. The results are representative of three independent experiments. (c) hMDMs were subjected to BCAT1 siRNA (si-BCAT1) or
non-targeting siRNA (Si-Control) treatment, followed by LPS stimulation (3 h, 100 ngml 1) before measuring BCAT1 expression levels (left panel),
OCR (middle panel) and ECAR (right panel). (d) Basal respiration, estimated ATP production, maximal respiration, glycolysis and glycolytic capacity in
si-Control and si-BCAT1 transfected, LPS-treated hMDMs. n¼4 hMDMs were used in at least ﬁve technical replicates. Error bars are s.e.m. Signiﬁcance
was tested using two-tailed Student’s t-test.
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experiment validated the presence of antibodies against type II
collagen and conﬁrmed that ERG240 did not interfere with
antibody production (Supplementary Figure 4).
Following completion of CIA, excised paws were analysed
for presence of inﬂammation, pannus formation, cartilage
damage and bone resorption by immunohistochemistry (Fig. 5c).
Despite its moderate effect on oedema formation, ERG240
markedly reduced the progression of the disease by decreasing
inﬂammation by 53%, cartilage degradation by 74% and pannus
formation and bone erosion by 86% (Fig. 5c). We found a
signiﬁcant decrease in joint oedema with ERG240 administration
only in the fore paws of the animals in the therapeutic study
(Supplementary Fig. 5). We further measured serum Tnf and
Tnfsf11 (RANKL) levels in CIA mice and found diminished
levels of these circulating markers upon ERG240 treatment
(Supplementary Fig. 6).
ERG240 treatment reduces macrophage inﬁltration in vivo. We
ﬁrst evaluated the potential effect of ERG240 on macrophage
migration and showed that ERG240 suppresses BMDMmigration
in a dose-dependent manner and with an IC50 value of
B5–10mM (Fig. 6a). Inhibition of migration was not incidental
to a cell death event as ERG240 did not affect cell numbers after
treatment of BMDM for 24 h (Fig. 6a). To further investigate the
mechanisms of action of ERG240 in vivo, excised paws were
tested for the presence of F4/80 by immunohistochemistry and
we found that there was a signiﬁcant reduction in F4/80þ
macrophages in the joints following ERG240 treatment (Fig. 6b).
Similarly to what we observed in CIA, macrophage inﬁltration
was signiﬁcantly reduced in nephrotoxic nephritis model as
the glomerular inﬁltration of CD68 (ED1)-positive cells were
signiﬁcantly decreased in ERG240-treated animals (Fig. 6c).
Discussion
A growing number of studies suggest that cellular metabolism,
immune response and inﬂammation are intimately linked
processes under common, evolutionary conserved regulatory
pathways33. The majority of the reports supporting the above
concept focus on glucose, glutamine and lipid metabolism or
document an association between deregulated metabolism and
immune pathology7,34,35. BCAA catabolism provides generally a
mechanism for regulating the levels of leucine, isoleucine and
valine, whose excess has been previously associated with neural
dysfunction36,37. Up-regulation of Bcat1 under pathological
conditions may serve to regulate the local levels of BCAAs and
especially leucine, which is known to activate the mammalian
target of rapamycin complex 1 (mTORC1). In CD4þ T cells,
Bcat1 regulates mTORC1 signalling and glycolytic metabolism,
highlighting the important role of leucine metabolism38. BCAA
transamination serves also as the source of amino groups for the
synthesis of non-essential amino acids such as glutamine and
alanine39. BCAT1 is considered as a secondary target of
gabapentin, a common antiepileptic and antinociceptive drug
that is known to bind with high afﬁnity to a2d 1 and a2d 2
subunits of voltage-activated calcium channels40. However,
gabapentin has been previously shown to display no apparent
anti-inﬂammatory effects41. The role of BCAA catabolism in
macrophage function is poorly described. In a recent report,
Meiser et al. observed an increased uptake of leucine in
RAW264.7 murine macrophage cell line stimulated with LPS
both in normoxia and hypoxia42, suggesting that LPS stimulation
in macrophages results in an increase of BCAA as an alternative
carbon source to glucose and glutamine42.
Here, we describe BCAT1 as the predominantly expressed
BCAT isoform in human macrophages. We found that
pharmacological blockade of BCAT1 resulted in decreased
oxygen consumption and glycolysis in LPS-treated macrophages.
We focused on early LPS activation (3 h) because major
transcriptome changes involving primary response genes occur
2-4 h following LPS stimulation in macrophages13,43 and
monocytes44 with some key Toll-like receptor4-dependent
markers such as Hif1a (ref. 45), Il1b (refs 43,46) and Irg1
(refs 19,47) detected as a rapid transcriptional activation
response. All these early response markers were found to be
tightly regulated by TCA in M(LPS)14,18, in particular Irg1 and its
enzymatic product, itaconate, which accumulates following
8–10 h LPS stimulation in primary mouse macrophages48 and
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RAW264.7 cells19. Itaconate is a bactericidal metabolite that
could have distinct roles depending on the pathological context49.
Besides its antimicrobial effects, itaconate has also been proposed
as an inhibitor of substrate level phosphorylation through its
effect on succinate-CoA ligase in RAW-264.7 cells50. Furthermore,
itaconic acid has been shown to inhibit SDH48,51,52 and a recent
study linked IRG1-itaconic acid production to modulation of
M2-like macrophage polarization in the revascularization of
ischaemic muscle53. Investigating pathways upstream and
downstream IRG1/itaconate are the focus of recent studies48,52,54
a b
c
d
IRG1
ACTB
1,000
2,000
3,000
4,000
Irg
1 
(re
lat
ive
 e
xp
re
ss
io
n)
Vehicle LPS LPS +
ERG240
P = 0.0022
Retention time (min)
vehicle
LPS
LPS + ERG240
52
38
Mr(Kda)
Ita
co
na
te
 
a
bu
nd
a
n
ce
5
10
15
20
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
Ve
hic
le
LP
S
LP
S +
 ER
G2
40
40
60
80
100
200
300
Mrc1 Klf4 Cd36
2,000
4,000
6,000
100
200
300
400
20
40
60
80
20
40
60
80
100
Fn1 Mmp9 Gsn Spp1
e
g
0
10
20
30
40
50
0
100
200
300
400
5
10
15
20
Gbp2b Gbp2 Gbp4
FP
KM
FP
KM
FP
KM
10
20
30
40
50
5
10
15
10
20
30
40
Ifit1 Ifit2 Ifit3
FP
KM
FP
KM
FP
KM
10
20
30
40
Gbp7
FP
KM
FP
KM
FP
KM
FP
KM
FP
KM
FP
KM
FP
KM
FP
KM
M2-like and extracellular matrix
10
20
30
40
0
10
20
30
40
Nos2 Il6
FP
KM
FP
KM
f
IFN-inducible GTPase
Pro-inflammatory (M1-like)
–
Lo
g 1
0(F
DR
)
Fold change
–6 –4 –2 0 2 4 6
LPS LPS +
ERG240
LPS + ERG240
(sequential)
50
100
Ita
co
na
te
 
(%
 of
 L
PS
)
* *
0
50
100
150
200
250
300
II6
Ifit1
Ifit3
Ifit2
Nos2
Gbp4
Gbp2b
Gbp7
Mmp9 Klf4
Mrc1
Gsn
Fn1
Spp1
Cd36
Gbp2
120,000
100,000
80,000
60,000
40,000
20,000
0
11.1 11.2 11.3 11.4 11.5
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms16040 ARTICLE
NATURE COMMUNICATIONS | 8:16040 | DOI: 10.1038/ncomms16040 |www.nature.com/naturecommunications 7
and will facilitate understanding the gene-metabolite links in
activated macrophages. This will be crucial in determining the
mechanisms by which BCAT1 regulate itaconate synthesis.
Metabolism in M(LPS) macrophages is characterized by high
levels of glycolysis, a fragmented TCA and relatively high levels
of some of its intermediates (succinate, citrate and itaconate).
By contrast, metabolism in M2 (or M(IL-4)) corresponds to high
levels of fatty acid oxidation (FAO) and oxidative phosphoryla-
tion even though the exact role of FAO in macrophage activation
states require further clariﬁcation55. Our ﬁndings indicating
(i) reduced ECAR levels as a result of BCAT1 inactivation in
human macrophages and (ii) anti-inﬂammatory effects of
ERG240, reversing the M1-like transcriptome in mouse
peritoneal macrophages, argue in favour of the involvement of
BCAA in M1/proinﬂammatory macrophage function. Although
the metabolic response of murine macrophages and dendritic
cells to LPS stimulation has been thoroughly explored15,17, the
bioenergetic proﬁle of human macrophages is not well described
and recent reports suggest that culturing conditions (M-CSF
versus GM-CSF) play an important role in their metabolic
reprogramming56. Here, we report that early LPS stimulation of
human macrophages resulted in an increase of ECAR, which is
indicative of increased glycolytic rate and is consistent with
previous results obtained in murine bone marrow derived and
peritoneal macrophages15.
The recently discovered discontinuity in the TCA cycle at the
Isocitrate Dehydrogenase 1 (IDH1) level, resulting in a ﬂux
re-direction towards citrate/aconitate has important implications
in terms of proinﬂammatory macrophage activation18. This
metabolic axis enables large production of fatty acids and
itaconate and our results suggest that leucine catabolism
through BCAT1 is a regulator of IRG1-dependent macrophage
activation. It is likely that BCAT1 regulates the production of
fatty acids and, in accordance with this, its expression levels in
human adipose tissue were found to correlate with weight regain,
making BCAT1 expression the best marker for this phenotype57.
Likewise, a down-regulation in BCAT1 expression was found to
correlate with a dietary weight loss program58.
Here, we demonstrate that Bcat1 is a druggable target for
controlling inﬂammation in two distinct chronic inﬂammatory
diseases characterized by antibody-mediated end-organ damage
with macrophage inﬁltration. The rat model of crescentic
glomerulonephritis in the WKY strain is dependent on macro-
phage inﬁltration and activation in response to glomerular
deposition of immunoglobulin21,59,60. Primary macrophages
from the WKY strain show a genetically determined Hif-1a-
mediated glycolytic transcriptome signature during their
differentiation61, suggesting a genetically determined metabolic
state that could explain their unique susceptibility to glomerular
inﬂammation. In RA, macrophages have been described as
the primary pathogenic drivers of the disease with ﬁbroblasts,
T and B lymphocytes playing secondary roles62. The protective
effect of Bcat1 inhibition in two LPS-independent inﬂammatory
models suggest that Bcat1 may have its regulatory role on
macrophages activated with different proinﬂammatory stimuli
and this is consistent with the in vitro observation that ERG240
inhibits Irg1 mRNA levels in TNF-activated human MDMs.
Nevertheless, the role of macrophage-derived BCAT1 in
inﬂammatory models can only be ﬁrmly established by using
conditional targeted gene deletion of Bcat1 in monocytes/
macrophages.
The druggability of Bcat1 in autoimmune disease was shown
with the utilization of ERG240, a novel Bcat1 inhibitor. ERG240
had an overall favourable bioavailability proﬁle with no
observable toxicity and, although administered at high concen-
trations, it showed promise as a therapeutic agent for auto-
immune diseases. While we acknowledge possible off-target
effects of ERG240 usage in vivo, the speciﬁcity towards Bcat1 and
Table 1 | Pharmacokinetics parameters determined after IV administration of 125mg kg 1 of ERG240 in mice.
C0 (lgml 1) t1/2 (h) AUClast (h lgml 1) AUCinf (h lgml 1) CL (mlmin 1 kg 1) MRT (h)
231 0.12 149 149 45.6 0.55
C0, drug concentration at time 0; t1/2, drug elimination half-life; AUClast, the area under the curve up to the last measurable concentration; AUCinf, the area under the curve extrapolated to inﬁnity;
CL: clearance rate; MRT, mean residence time.
Table 2 | Pharmacokinetics parameters determined after oral administration of 500mg kg 1 of ERG240 in mice.
Cmax (lgml 1) Tmax (h) AUClast (h lgml 1) AUCinf (h lgml 1) MRT (h) F (%)
351 1.0 794 794 1.24 100
Cmax, maximum drug concentration in plasma; tmax, time to Cmax; F, bioavailability.
Figure 4 | Bcat1 inhibition blocks itaconate production in vivo and polarizes peritoneal macrophages. Mouse peritoneal macrophages from vehicle
(saline), LPS-injected (1.5mg kg 1) or LPSþ ERG240 (500mg kg 1)–injected mice were isolated and pooled 24 h following i.p. injection (n¼6 mice per
group). Irg1 protein (a), mRNA (b) levels, as well as itaconate measurements by GC/MS (c) are shown. The lower panel (c) shows itaconate levels in
peritoneal macrophages isolated from mice injected either with LPS or LPS þ ERG240 or a sequential treatment where LPS was ﬁrst injected for 3 h,
followed by ERG240 (LPSþ ERG240 (sequential)). Peritoneal macrophages were collected 24 h following the LPS injection. n¼ 3 mice/group.
(d) Protein–protein interaction (PPI) network in 100 top (97 annotated) differentially expressed genes between LPS and LPSþ ERG240 treated mouse
peritoneal macrophages illustrated by STRING (high conﬁdence score¼0.7). The IFN-inducible GTPase cluster is shown within a dashed circle.
(e) Distribution of the fold changes and the FDR-adjusted P values ( log10 (FDR)) for the comparison between LPS and LPSþ ERG240 treated
macrophages. The IFN- inducible GTPase genes, M1-like, M2-like and extracellular matrix transcripts are shown in blue. (f) Fragments per kilobase of
transcript per Million mapped reads (FPKM) values for Nos2, Il6 are shown in vehicle, LPS and LPSþ ERG240-treated peritoneal macrophages. (g) FPKM
values for Iﬁt1, Iﬁt2, Iﬁt3, Gbp1, Gbp2, Gbp4, Gbp7, Mrc1, Klf4, Cd36, Fn1, Mmp9, Gsn and Spp1. FPKM¼ 1 is shown as a dashed line to denote minimal
expression levels. All transcripts analysed by RNA-seq (f,g) show signiﬁcant FPKM upon ERG240 treatment when compared to LPS group (FDRo10 73).
Error bars are s.e.m. Signiﬁcance was tested using one-way ANOVA. *Po0.05 by ANOVA.
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not its mitochondrial isoform (Bcat2) is supported by the
contrasting physiological consequences observed as a result of
disrupting Bcat1 and Bcat2 genes, individually. Bcat2 / mice
show 50-fold elevation in plasma BCAA concentrations, which
leads to organ hypertrophy63, seizures and death (unpublished
observation) if the animals are not offered a low-branched-chain
amino acid diet64. In contrast, Bcat1 / mice have normal
plasma BCAA concentrations when fed a standard rodent chow38,
suggesting that if there were any non-speciﬁc pharmacological
effects of ERG240 towards Bcat2 in vivo, this would possibly lead to
notable pathological consequences which were not observed in
neither of the disease models in rats and mice.
In summary, we show that blocking Bcat1 results in therapeutic
outcome in two independent models of autoimmune diseases
with end-organ damage (joints and glomeruli). We show that
macrophages express relatively high amounts of Bcat1 and
blocking its activity inhibit Irg1/itaconate levels in human
macrophages, and in vivo. Furthermore, Bcat1 inhibition is also
associated with reduced macrophage migration in vitro and
decreased tissue inﬁltration in arthritis and glomerulonephritis.
Thus, macrophage BCAT1 and its ability to interfere with
metabolic reprogramming is an attractive pharmacological target
for the treatment of chronic inﬂammatory diseases.
Methods
Animals. DBA/1 mice (male, 6–8 weeks old) used in CIA experiments were
purchased from Harlan Sprague Dawley Inc. WKY (male, 16-weeks old,
WKY/NCrl) rats used for NTN experiments were purchased from Charles River
UK. All mice and rats were used straight from the source by housing them until the
appropriate experimental age. All procedures were performed in accordance to
institutional guidelines and procedures approved by the UK Home Ofﬁce
(United Kingdom Animals Scientiﬁc ProceduresAct, 1986) or followed the
requirements of the United States of America Animal Welfare Act (1966) and the
guidelines outlined in the Guide for the Care and Use of Laboratory Animals,
8th Edition (2011).
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Cells and reagents. Human monocyte-derived macrophages were differentiated
from buffy coats from healthy donors using gradient separation (Histopaque 1077,
Sigma) and adhesion puriﬁcation. Following Histopaque separation, peripheral
blood mononuclear cells were re-suspended in RPMI (Life Technologies) and
monocytes were puriﬁed by adherence for 1 h at 37 C, 5% CO2. The monolayer
was washed 6 times with HBSS to remove non-adherent cells and monocytes were
matured for 5 days in RPMI containing 100 ngml 1 M-CSF (PeproTech, UK)
and 10% Fetal Calf Serum (FCS, Labtech International). Macrophage purity was
conﬁrmed by immunohistochemical assessment of CD68 and 499% cells were
CD68þ . For migration assays, C57BL/6 mouse bone marrow derived macrophages
(BMDMs) were purchased from Cell Biologics. The cells were cultured in culture
media according to manufacturer’s instructions. The phenotype of the BMDMs
was veriﬁed by determining the expression of macrophage marker CD68 by whole
cell ELISA. The migration assay is detailed in Supplementary Methods. For BCAA
deprivation assay, RPMI 1640 containing L-Glutamine but no BCAAs was used.
Lipopolysaccharide was purchased from Sigma (LPS; Escherichia coli serotype
0111:B4; Cat No L4391) and the antibodies used in Western Blot analyses are as
follows: IL-1b (Cell Signaling Technologies, #12703; D3U3E, dilution 1/1,000),
IRG1 (Abcam, ab122624, rabbit polyclonal, dilution, 1/1,000), HIF-1a (NOVUS
biological, NB100-449, rabbit polyclonal, dilution 1/2,000), ACTB (Santa Cruz,
sc-47778, b-Actin (C4), mouse monoclonal, dilution 1/2,000), BCAT1 (anti Bcat1
raised in rabbit, produced in Susan Hutson’s laboratory4,65, 8382, dilution
1/120,000), TUBB (Cell Signaling Technologies, #2128, rabbit monoclonal,
dilution 1/30,000).
Western blot and RNA analysis. hMDMs were lysed in Laemmli sample buffer
supplemented with protease inhibitors and resolved by SDS-PAGE, transferred
into PVDF membranes, and subjected to immunoblotting with the
primary antibodies described above and secondary detection antibodies. The
probed proteins were detected using SuperSignal West Femto Chemiluminescent
Substrate (Thermo Fisher Scientiﬁc Inc., Rockford, IL). Uncropped scans of
western blots presented in the main and Supplementary Figures are provided in
Supplementary Fig. 8. qRT-PCR reactions were performed using the Viaa 7
Real-Time PCR system (Life technologies). A two-step protocol was used
beginning with cDNA synthesis with iScript select (Bio-Rad) followed by PCR
using Brilliant II SYBR Green QPCR Master Mix (Agilent). A total of 10 ng of
cDNA per sample was used. Viia 7 RUO Software was used for the determination
of Ct values. Results were analysed using the comparative Ct method and each
sample was normalized to the indicated reference gene, to account for any
cDNA loading differences. For RNAi, hMDMs were re-plated in six-well plates
(1 106 cells per well) in RPMI (Invitrogen) overnight and transfected with
siGENOME SMARTpool for human BCAT1 (100 nM, Dharmacon SMART pool)
or non-targeting siRNA pool as the scrambled control siRNA using
Dharmafect 1 (1:50, Dharmacon) as a transfection reagent in OPTIMEM medium
(Invitrogen). Following 8 h incubation with OPTIMEM media containing either
BCAT1 or non-targeting siRNA, the culture media was washed and cells were
further cultured for 48 h in presence of RPMI media containing M-CSF and FCS.
Cells were then used either for extracellular ﬂux analysis (see below) or IRG1,
BCAT1, ACTB and TUBB Western Blot analysis. Primer sequences for siRNA
and qRT-PCR are provided in Supplementary Fig. 7.
Metabolism assays. Real-time measurements of OCR and ECAR were performed
using a Seahorse XF96 Extracellular Flux Analyzer (Seahorse Bioscience). hMDMs
cultured for 5 days in presence of RPMI containing M-CSF (100 ngml 1) and FCS
(10%) were washed and incubated with either ERG240 or LPS or a combination of
both for 3 h. Cells were then washed, re-suspended using the non-enzymatic cell
dissociation buffer (Sigma) and 5 105 hMDMs were seeded as a monolayer in a
96-well microplate containing XF Assay Modiﬁed DMEM. Glucose and different
metabolic drugs were injected during real-time measurements of OCR and ECAR.
Basal respiration was calculated as the last measurement before addition of
oligomycin – non mitochondrial respiration (minimum rate measurement after
Rot/AntA). Estimated ATP production designates the last measurement before
addition of oligomycin – minimum rate after oligomycin. Maximal respiration
is shown as the maximum rate measurement after addition of FCCP – non
mitochondrial respiration (minimum rate measurement after Rot/AntA).
Glycolysis refers to ECAR values before the addition of oligomycin – ECAR
values before the addition of glucose. Glycolytic capacity shows ECAR values
following addition of oligomycin – ECAR values before the addition of glucose.
In RNAi experiments, hMDMs transfected with either BCAT1 siRNA or control
(non-targeting) siRNA were seeded in a 96-well microplate, LPS-stimulated
(100 ngml 1, 3 h) and real-time measurements of OCR and ECAR were recorded,
as described above.
Mouse i.p. injection of LPS and ERG240. The procedure was performed by
Washington Biotechnology Inc. (Baltimore, MD). 6–8 week old female C57BL6
mice were administered ERG240 (500mg kg 1) by intraperitoneal route 30min
before the i.p. LPS injection (from E. coli strain 055:B5, 1.5mg kg 1). Same dose of
ERG240 was administered a second time, 8 h following the ﬁrst injection of LPS.
Peritoneal macrophages were harvested 24 h after the LPS injection and results
from three groups (vehicle, LPS only, LPSþERG240; n¼ 6 mice in each group)
were analysed in terms of IRG1 and itaconate level measurements.
Macrophage itaconate and citrate measurements by GC/MS. For itaconate,
cells pellets containing 1.5 106 hMDMs were quenched with 400 ml of methanol,
previously chilled at  20 C. After addition of 400ml of cold (4 C) ultrapure
water, cell pellets were vortexed brieﬂy and then allowed to stand for 10min on ice.
Following addition of 400ml of GC/MS grade dichloromethane, previously chilled
at  20 C, samples were vortexed again and centrifuged at 14,000g for 10min at
4 C. The aqueous layer of the samples was collected and lyophilized. Dried
materials were dissolved in 40 ml of MOX solution, which is prepared by allowing
20mg of methoxamine HCl (Sigma Aldrich) to dissolve in 500 ml pyridine for
30min at room temperature. Metabolites dissolved in MOX were incubated at
45 C for 60min, derivatized by adding 60 ml of N-methyl-N-(trimethylsilyl)
triﬂuoroacetamide (MSFTA, Mecherey-Nagel) and incubated at 45 C for 30min.
After a brief centrifugation, derivatized metabolites were transferred into clean
GC/MS vials and analysed for the presence of itaconic acid (itaconate) using a
7890A GC System (Agilent Technologies) equipped with an Agilent J&W DB-5ms
column (30m, 0.25mm, 0.25 mm), connected to an 5975C Triple-Axis MS Detector
(Agilent Technologies) and outﬁtted with an autosampler. The MS source was held
at 230 C and the quadrupole at 150 C. The GC oven temperature was held at
50 C for 5min, increased to 240 C at a rate of 10 Cmin 1, held at 240 C for
5min and increased to 300 C at a rate of 10 Cmin 1. A volume of 1 ml was
injected in the system in a 1:3 split mode. The amount of itaconate present in the
sample was determined after peak integration. For citrate, the frozen cell pellets
were re-suspended in ice-cold ethanol-phosphate buffer. Cells were lysed by three
freeze-thaw cycles and sonication. Samples were centrifuged and the supernatant
was used for further analysis. The GC/MS was performed by Biocrates
(BIOCRATES Life Sciences AG, Innsbruck, Austria) and the citrate quantiﬁcation
was performed using their commercially available Kit plates, according to
the manufacturer’s instructions. After derivatization to its corresponding
methoxime-trimethylsilyl (MeOx-TMS) derivative, citrate levels were determined
by GC/MS using Agilent 7890 GC/5975 MSD (Agilent, Santa Clara, USA).
Pretreated samples were evaporated to complete dryness and subjected to a
two-step methoximation-silylation derivatization. N-methyl-N-(trimethylsilyl)
triﬂuoroacetamide (MSTFA) was used as silylation reagent. Split injection was
performed and chromatograms were recorded in selected ion monitoring mode.
External standard calibration curves and ten internal standards were used to
calculate concentrations of individual energy metabolites. Data were quantiﬁed
using the appropriate MS software (Agilent, Masshunter) and imported into
Biocrates MetIDQ software for further analysis.
In vivo pharmacokinetics. The experiment was performed by Euroﬁns Panlabs
Inc. Brieﬂy, fasting pharmacokinetic parameters were obtained after administration
of 125mg kg 1 i.v. or 500mg kg 1 p.o ERG240 to ICR mice and blood collection
at 3, 10, 30, 60, 120 and 240min (i.v. dosing) or 10, 30, 60, 120, 240 and 360min
(p.o. dosing). Each animal was subjected to a single blood draw and 3 animals per
time point were used. Parameters were obtained from non-compartmental analysis
of the plasma data using WinNonlin. Experimental details are provided in
Supplementary Methods.
RNA-sequencing. Total RNA was extracted from hMDMs and mouse peritoneal
macrophages using Trizol (Invitrogen) according to manufacturer’s instructions
with an additional puriﬁcation step by on-column DNase treatment using the
RNase-free DNase Kit (Qiagen) to ensure elimination of any genomic DNA.
The integrity and quantity of total RNA was determined using a NanoDrop 1000
spectrophotometer (Thermo Fisher Scientiﬁc) and Agilent 2100 Bioanalyzer
(Agilent Technologies). In total 500 ng of total RNA was used to generate RNA-seq
libraries using TruSeq RNA sample preparation kit (Illumina) according to the
manufacturer’s instructions (see Supplementary Methods for detailed library
preparation, mapping and sequencing protocols).
Collagen-induced arthritis in mice. DBA/1 mice (6–8 weeks old from Harlan
Sprague Dawley Inc.) were injected s.c. with 100mg of bovine type II collagen
emulsiﬁed in complete Freund’s adjuvant (Sigma). At day 21 following primary
immunization, the mice were given a booster injection of 100 mg of bovine type II
collagen emulsiﬁed in incomplete Freund’s adjuvant. The prophylactic arm of the
study involved water-treated (vehicle control, n¼ 6) and ERG240-treated
(720mg kg 1, o.p., qdx5, 3 weeks, n¼ 10) animals, while the therapeutic arm of
the study involved water-treated (vehicle control, n¼ 10) and ERG240-treated
(1,000mg kg 1, o.p., qdx5, 4 weeks, n¼ 10) animals. Paraﬁn-embedded paws were
sectioned at B5 mm. One slide from each paw was stained with hematoxylin and
eosin (H&E) and served as a reference, while four additional slides were stained
using antibodies against F4/80 (AbD Serotec). The expression of the above markers
in the joints of the preserved CIA tissues was scored according to the following
scale: 0¼ no staining; 1¼minimal; 2¼mild; 3¼moderate; 4¼marked; and
5¼ diffuse and severe staining (see Supplementary Methods for detailed histolo-
gical evaluation of CIA tissues). Serum levels of TNF and RANKL were analysed
using relevant ELISA kits from Biolegend (TNF-a) and Abcam (RANKL)
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according to the manufacturers’ instructions. Details for determining the presence
of antibodies against type II collagen are provided in Supplementary Methods.
Nephrotoxic nephritis in the WKY rat. Nephrotoxic nephritis (NTN) was
induced in twelve week old male Wistar-Kyoto (WKY) rats by intravenous
injection of 0.1ml of nephrotoxic serum (NTS), as previously described66.
Five WKY rats received ERG240 (250mg kg 1) orally in 0.1%
carboxymethylcellulose once a day for a duration of 10 days whereas the vehicle
treated WKY rats had carboxymethylcellulose only for the same period. Nine days
following NTS injection, urine was collected by placing rats in metabolic cages for
24 h with free access to food and water. Proteinuria was determined by the
sulphosalicylic acid test and serum creatinine by the Creatinine Assay Kit (Abcam).
After 10 or 28 days of NTN induction, rats were culled and the kidney was
formalin ﬁxed and parafﬁn embedded for immunohistochemistry. To quantify the
number of macrophages inﬁltrating the glomeruli, formalin-ﬁxed parafﬁn-
embedded kidney sections were stained with mouse monoclonal antibody to ED-1
(Serotec, Oxford, UK), followed by an HRP-labelled anti-mouse polymer
development system (Dako Ltd, UK). For the evaluation of total collagen, renal
tissues were stained with Sirius red. For Col1a1 immunoﬂuorescence, sections were
blocked with BSA, incubated with the Col1a1 primary antibody raised in goat
(Southern Biotech, 1/40 dilution), washed and re-incubated with secondary
antibody (donkey anti-goat-FITC, 1/100 dilution, Abcam). For ED-1 staining, the
cellular inﬁltrates in 20 consecutive glomeruli were quantiﬁed using an automated
image analysis software (ImagePro Plus, Media Cybernetics, Bethesda, MD) and
expressed as a percentage of total glomerular cross sectional area.
Statistical analyses. Data are presented as mean±s.e.m. and analysed using
GraphPad Prism software (version 7.02; GraphPad). The Mann–Whitney or
Student’s t-tests were used for comparison of two groups. Differences in
percentage of itaconate in human samples were tested for signiﬁcance using a
one-sample-t-test. One-way or two-way ANOVA analyses (followed by Tukey’s or
Dunnet’s or Sidak’s multiple comparison tests) were used for comparative analyses
of three or more groups.
Data availability. Mouse sequence data that support the ﬁndings of this study
have been deposited in the European Nucleotide Archive with the primary
accession code PRJEB20215. The authors declare that all other data supporting
the ﬁndings of this study are available within the paper and its Supplementary
Information ﬁles or are available from the corresponding authors on request.
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